Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Irinotecan Plus S-1 Followed by Hepatectomy for a Patient with Initially Unresectable Colorectal Liver Metastases, Who Showed Severe Drug Rash with Oxaliplatin Plus 5-FU and Leucovorin (FOLFOX).

Komori H, Beppu T, Sakamoto Y, Miyamoto Y, Hayashi H, Imai K, Nitta H, Watanabe M, Baba H.

Case Rep Gastrointest Med. 2014;2014:906759. doi: 10.1155/2014/906759. Epub 2014 Jun 17.

2.

Efficacy of postoperative oxaliplatin- or irinotecan-based chemotherapy after curative resection of synchronous liver metastases from colorectal cancer.

Hsu HC, Chou WC, Shen WC, Wu CE, Chen JS, Liau CT, Lin YC, Yang TS.

Anticancer Res. 2013 Aug;33(8):3317-25.

PMID:
23898098
3.

Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure.

Boige V, Malka D, Elias D, Castaing M, De Baere T, Goere D, Dromain C, Pocard M, Ducreux M.

Ann Surg Oncol. 2008 Jan;15(1):219-26. Epub 2007 Sep 26.

PMID:
17896145
5.

Role of oxaliplatin combined with 5-fluorouracil and folinic acid in the first- and second-line treatment of advanced colorectal cancer.

Jonker D, Rumble RB, Maroun J; Gastrointestinal Cancer Disease Site Groupof Cancer Care Ontario’s Program in Evidence-Based Care.

Curr Oncol. 2006 Oct;13(5):173-84.

6.

S-1 and irinotecan with or without bevacizumab versus 5-fluorouracil and leucovorin plus oxaliplatin with or without bevacizumab in metastatic colorectal cancer: a pooled analysis of four phase II studies.

Iwasa S, Nagashima K, Yamaguchi T, Matsumoto H, Ichikawa Y, Goto A, Yasui H, Kato K, Okita NT, Shimada Y, Yamada Y.

Cancer Chemother Pharmacol. 2015 Sep;76(3):605-14. doi: 10.1007/s00280-015-2834-4. Epub 2015 Jul 29.

PMID:
26220845
7.

A 5-year recurrence-free survivor with over ten colorectal liver metastases undergoing FOLFOX plus bevacizumab followed by two-stage hepatectomy.

Tamaoki Y, Beppu T, Sakamoto Y, Imai K, Hayashi H, Nitta H, Hashimoto D, Miyamoto Y, Tsuruta Y, Chikamoto A, Baba H.

Surg Case Rep. 2015 Dec;1(1):111. doi: 10.1186/s40792-015-0113-6. Epub 2015 Oct 29.

8.

Adjuvant oxaliplatin- or irinotecan-containing chemotherapy improves overall survival following resection of metachronous colorectal liver metastases.

Liu JH, Hsieh YY, Chen WS, Hsu YN, Chau GY, Teng HW, King KL, Lin TC, Tzeng CH, Lin JK.

Int J Colorectal Dis. 2010 Oct;25(10):1243-9. doi: 10.1007/s00384-010-0996-4. Epub 2010 Jun 24.

9.

Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival.

Adam R, Delvart V, Pascal G, Valeanu A, Castaing D, Azoulay D, Giacchetti S, Paule B, Kunstlinger F, Ghémard O, Levi F, Bismuth H.

Ann Surg. 2004 Oct;240(4):644-57; discussion 657-8.

10.

Adjuvant chemotherapy with FOLFOX for primary colorectal cancer is associated with increased somatic gene mutations and inferior survival in patients undergoing hepatectomy for metachronous liver metastases.

Andreou A, Kopetz S, Maru DM, Chen SS, Zimmitti G, Brouquet A, Shindoh J, Curley SA, Garrett C, Overman MJ, Aloia TA, Vauthey JN.

Ann Surg. 2012 Oct;256(4):642-50. doi: 10.1097/SLA.0b013e31826b4dcc.

11.
12.

Bevacizumab in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with metastatic colorectal cancer who were previously treated with oxaliplatin-containing regimens: a multicenter observational cohort study (TCTG 2nd-BV study).

Moriwaki T, Bando H, Takashima A, Yamazaki K, Esaki T, Yamashita K, Fukunaga M, Miyake Y, Katsumata K, Kato S, Satoh T, Ozeki M, Baba E, Yoshida S, Boku N, Hyodo I.

Med Oncol. 2012 Dec;29(4):2842-8. doi: 10.1007/s12032-011-0151-2. Epub 2011 Dec 31.

PMID:
22209842
13.

The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.

Hind D, Tappenden P, Tumur I, Eggington S, Sutcliffe P, Ryan A.

Health Technol Assess. 2008 May;12(15):iii-ix, xi-162. Review.

14.

Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).

Muro K, Boku N, Shimada Y, Tsuji A, Sameshima S, Baba H, Satoh T, Denda T, Ina K, Nishina T, Yamaguchi K, Takiuchi H, Esaki T, Tokunaga S, Kuwano H, Komatsu Y, Watanabe M, Hyodo I, Morita S, Sugihara K.

Lancet Oncol. 2010 Sep;11(9):853-60. doi: 10.1016/S1470-2045(10)70181-9. Epub 2010 Aug 12.

PMID:
20708966
15.

[A long survival case of sigmoid colon cancer patient with initially unresectable hepatic metastases].

Oshima T, Noda M, Tanaka K, Kuno T, Tsukamoto K, Hashimoto A, Gega M, Yagyuu T, Yoshikawa R, Ikeuchi H, Yanagi H, Yamamura T.

Gan To Kagaku Ryoho. 2007 Apr;34(4):631-4. Japanese.

PMID:
17431355
16.

Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial.

Gruenberger T, Bridgewater J, Chau I, García Alfonso P, Rivoire M, Mudan S, Lasserre S, Hermann F, Waterkamp D, Adam R.

Ann Oncol. 2015 Apr;26(4):702-8. doi: 10.1093/annonc/mdu580. Epub 2014 Dec 23.

PMID:
25538173
17.

Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial.

Garufi C, Torsello A, Tumolo S, Ettorre GM, Zeuli M, Campanella C, Vennarecci G, Mottolese M, Sperduti I, Cognetti F.

Br J Cancer. 2010 Nov 9;103(10):1542-7. doi: 10.1038/sj.bjc.6605940. Epub 2010 Oct 19.

18.

Successful treatment of conversion chemotherapy for initially unresectable synchronous colorectal liver metastasis.

Baba K, Oshita A, Kohyama M, Inoue S, Kuroo Y, Yamaguchi T, Nakamura H, Sugiyama Y, Tazaki T, Sasaki M, Imamura Y, Daimaru Y, Ohdan H, Nakamitsu A.

World J Gastroenterol. 2015 Feb 14;21(6):1982-8. doi: 10.3748/wjg.v21.i6.1982.

19.

Hepatic artery infusion therapy is effective for chemotherapy-resistant liver metastatic colorectal cancer.

Goi T, Naruse T, Kimura Y, Fujimoto D, Morikawa M, Koneri K, Yamaguchi A.

World J Surg Oncol. 2015 Oct 9;13:296. doi: 10.1186/s12957-015-0704-5.

20.

Efficacy and safety of irinotecan plus S-1 (IRIS) therapy to treat advanced/recurrent colorectal cancer.

Higashi D, Egawa Y, Hirano Y, Hirano K, Miyake T, Takahashi H, Uwatoko S, Abe S, Yamamoto S, Mikami K, Futami K, Maekawa T, Inoue R, Miyazaki M.

Anticancer Res. 2014 Aug;34(8):4595-9.

PMID:
25075105

Supplemental Content

Support Center